share_log

JMP Securities Maintains Market Outperform on CureVac, Lowers Price Target to $16

Benzinga ·  Aug 16 20:02  · Ratings

JMP Securities analyst Roy Buchanan maintains CureVac (NASDAQ:CVAC) with a Market Outperform and lowers the price target from $18 to $16.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment